Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05074940 · OUTCOME

Quality of Life - Measured Via FACT-HN

Amivantamab in Adenoid Cystic Carcinoma · Source last updated 2026-05-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
units on a scale
Interval / dispersion
Standard Deviation
Time frame
2 years

What was measured

The FACT HN is a patient reported outcome (PRO) measure that assesses health related quality of life in patients with head and neck cancer. It evaluates general cancer related quality of life as well as symptoms and concerns specific to head and neck cancer. The total score range is 0 - 144, with higher scores reflecting more positive perceptions across areas of well-being. A difference score from end of treatment and pre-treatment was calculated.

Analysis population: 19 patients with evaluable inventory data

Groups in this outcome

Amivantamab

Amivantamab weekly for the first cycle and biweekly thereafter. Amivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Amivantamab19

Reported measurements

Source class 1
Values in units on a scale · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Amivantamab-0.78.4Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        8.4
        value
        -0.7
denoms
  1. counts
    1. group Id
      OG000
      value
      19
    units
    Participants
description
The FACT HN is a patient reported outcome (PRO) measure that assesses health related quality of life in patients with head and neck cancer. It evaluates general cancer related quality of life as well as symptoms and concerns specific to head and neck cancer. The total score range is 0 - 144, with higher scores reflecting more positive perceptions across areas of well-being. A difference score from end of treatment and pre-treatment was calculated.
dispersion Type
Standard Deviation
groups
  1. description
    Amivantamab weekly for the first cycle and biweekly thereafter. Amivantamab: Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).
    id
    OG000
    title
    Amivantamab
param Type
MEAN
population Description
19 patients with evaluable inventory data
reporting Status
POSTED
time Frame
2 years
title
Quality of Life - Measured Via FACT-HN
type
OTHER_PRE_SPECIFIED
unit Of Measure
units on a scale

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice